1. |
responsiveness to its antidiabetic effect. Diabets Care, 2003, 26(9): 2493-2499.
|
2. |
Metabolic Syndrome Treated with Glimepiride: A Twelve-Month, Multicenter, Double-Blind, Randomized, Controlled, Parallel-Group Trial. Clinical Therapeutics, 2004, 26(5): 746-754.
|
3. |
Douglas JA, Erdos MR, Watanabe RM, et al. The Peroxisome Proliferator–Activated Receptor- 2 Pro12Ala Variant: Association With Type 2 Diabetes and Trait Differences. Diabetes, 2001, 50(4): 886- 890.
|
4. |
Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25(10): l737- l743.
|
5. |
MartensF M, VisserenF L, LemayJ, et al. Metabolic and additional vascular effects of thiazolidinediones. Drug, 2002, 62(10): 1463-1480.
|
6. |
徐成斌. 代谢综合征. 国外医学内分泌学分册. 2005, 25(1): 3-6.
|
7. |
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trail. Lancet, 2005, 366(9493): 1279-1289.
|
8. |
Marx N & Hombach V. Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells (in German). Zeitschrift für Kardiologie, 2001, 90(7): 470-477.
|
9. |
Goetze S, XI XP, Kawano H, et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. Journal of Cardiovascular Pharmacology, 1999, 33(5): 798-806.
|
10. |
Jiang C, Ting AT, Seed B. PPAR-agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391(6662): 82-86.
|
11. |
Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferatoractivated receptors and induces apoptosis of human monocytederived macrophages. J Biol Chem, 1998, 273(40): 25573-25580.
|
12. |
Koshi y ama H, Shimono D, Kuwamur a N, et al . Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab, 2001, 86(7): 3452-3456.
|
13. |
Satoh N, Ogawa Y, Usul T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the.
|
14. |
Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002, 106(6): 679-684.
|
15. |
Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol, 2005, 45(12): 1925-1931.
|
16. |
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2005, 28(7): 1547-1554.
|
17. |
Fullert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebocontrolled study. J Clin Endocrinol Metab, 2002, 87(12): 5503-5506.
|
18. |
Raji A, Williams GH, Seely EW, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care, 2003, 26(1): 172-178.
|
19. |
Alberti KGMM, Zimmet PZ, WHO Consultation. Definition,diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med, 1998, 15(7): 539-553.
|
20. |
Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (Adult treatment Panel Ⅲ). Executive summary of the third report of the National Cholesteral Eduation Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. J Am Med Assoc, 2001, 285(19): 2486-2497.
|
21. |
Barclay L. Medscape Medical News. New definition of the metabolic syndrome: a newsmaker interview with Sir George Alberti, MA, DPhil, BMBCh. Available at: http: //www. medscape. com/viewarticle/504382 Accessed July 8, 2005.
|
22. |
吴泰相, 刘关键. 隐蔽分组(分配隐藏)和盲法的概念、实施与报告. 中国循证医学杂志, 2007, 7(3): 222-225.
|
23. |
Cao Z, Zhou YJ, Zhao YX, et al. Rosiglitazone could improve clinical outcome after coronary stent implantation in nondiabetes patients with metabolic syndrome. Chinese Medical Journal, 2006, 119(14): 1171-1175.
|
24. |
Samaha FF, Szapary PO, Iqbal N, et al. Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome. Arterioscler Thromb Vasc Biol, 2006, 26(3): 624-630.
|
25. |
Derosa G, Cicero AFG, Gaddi A, et al. Metabolic Effects of Pioglitazone and Rosiglitazone in Patients with Diabetes and.
|
26. |
Derosa G, Gaddi AV, Ciccarelli L, et al. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. The journal of international medical resesarch, 2005, 33(3): 284-294.
|
27. |
Derosa G, D’Angelo A, Ragonesi PD, et al. Metformin–pioglitazone and metformin- rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacy and Therapeutics, 2006, 31(4): 375-383.
|
28. |
Esposito K, Ciotola M, Carleo D, et al. Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome. Diabetes Care, 2006, 29(5): 1071-1076.
|
29. |
Szapary PO, Bloedon LT, Samaha FF, et al. Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome. Arterioscler Thromb Vasc Biol, 2006, 26(1): 182-188.
|
30. |
Wang TD, Chen WJ, Lin JW, et al. Effects of Rosiglitazone on Endothelial Function, C-Reactive Protein, and Components of the Metabolic Syndrome in Nondiabetic Patients With th Metabolic Syndrome. Am J Cardiol, 2004, 93(3): 362-365.
|
31. |
Wang TD, Chen WJ, Cheng WC, et al. Relation of Improvement in Endothelium-Dependent Flow-Mediated Vasodilation After Rosiglitazone to Changes in Asymmetric Dimethylarginine, Endothelin-1, and C-Reactive Protein in Nondiabetic Patients With the Metabolic Syndrome. Am J Cardiol, 2006, 98(8): 1057-1062.
|
32. |
徐凤霞, 商宏伟, 李金华, 等. 罗格列酮对血糖正常的MS患者血管内皮功能和C反应蛋白的影响. 中国临床药理学杂志, 2005, 22(1): 15-17.
|
33. |
Isomaa B, Almgren P, Tuonfi T, et a1. Cardiovascular morbidity and mortality associate with the metabolic syndrome. Diabetes Care, 2001, 24(4): 683-689.
|
34. |
Lakka HM, laaksonen DE, Lakka TA, et a1. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA, 2002, 288(21): 2709-2716.
|
35. |
Hunt KJ, Resendz RG, Williams K, et al. NCEP versus WHO metabolic syndrome in relation to all cause and cardiovascular mortality in the San Antonio Heart Study (SAHS) [abstract]. Diabetes, 2003, 52(1): A221-227.
|